Fig. 8: Western blot analysis of purified recombinant AMPK and Src following exposure to [L2Zn3]6+ and [L2Cu3]6+ and the effects of [L2Zn3]6+ and [L2Cu3]6+ treatment on cellular phospho-Thr172 AMPKα levels. | Nature Communications

Fig. 8: Western blot analysis of purified recombinant AMPK and Src following exposure to [L2Zn3]6+ and [L2Cu3]6+ and the effects of [L2Zn3]6+ and [L2Cu3]6+ treatment on cellular phospho-Thr172 AMPKα levels.

From: Self-assembly of an anion receptor with metal-dependent kinase inhibition and potent in vitro anti-cancer properties

Fig. 8

a Purified AMPK and Src enzymes were incubated with complexes (50 μM) for 4 h in the presence of ATP prior to analysis. b ARPE-19 non-cancer cells and HCT116 cancer cells were treated with 10 µM [L2Cu3]6+ or [L2Zn3]6+ for 4 h prior to harvesting and immunoblot analysis. Similar results were obtained in a minimum of n = 2 independent experiments.

Back to article page